#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The objective of this paper was using the Essential Medicines List for children by the World Health Organization ( WHO ) to create a provisional pediatric biopharmaceutics classification system ( pBCS ) for oral drugs and to compare our results with the BCS for adults ( aBCS ) .
3-1	17-20	The	abstract[3]	new[3]	_	_
3-2	21-30	objective	abstract[3]	new[3]	_	_
3-3	31-33	of	abstract[3]	new[3]	_	_
3-4	34-38	this	abstract[3]|object[4]	new[3]|new[4]	_	_
3-5	39-44	paper	abstract[3]|object[4]	new[3]|new[4]	_	_
3-6	45-48	was	_	_	_	_
3-7	49-54	using	_	_	_	_
3-8	55-58	the	object[6]	new[6]	coref	4-8[20_6]
3-9	59-68	Essential	object[6]	new[6]	_	_
3-10	69-78	Medicines	quantity|object[6]	new|new[6]	coref	4-13[21_0]
3-11	79-83	List	object[6]	new[6]	_	_
3-12	84-87	for	object[6]	new[6]	_	_
3-13	88-96	children	object[6]|person[7]	new[6]|new[7]	coref	4-16[0_7]
3-14	97-99	by	object[6]|person[7]	new[6]|new[7]	_	_
3-15	100-103	the	object[6]|person[7]|organization[8]	new[6]|new[7]|new[8]	_	_
3-16	104-109	World	object[6]|person[7]|organization[8]	new[6]|new[7]|new[8]	_	_
3-17	110-116	Health	object[6]|person[7]|organization[8]	new[6]|new[7]|new[8]	_	_
3-18	117-129	Organization	object[6]|person[7]|organization[8]	new[6]|new[7]|new[8]	_	_
3-19	130-131	(	_	_	_	_
3-20	132-135	WHO	_	_	_	_
3-21	136-137	)	_	_	_	_
3-22	138-140	to	_	_	_	_
3-23	141-147	create	_	_	_	_
3-24	148-149	a	abstract[11]	new[11]	appos	3-31[0_11]
3-25	150-161	provisional	abstract[11]	new[11]	_	_
3-26	162-171	pediatric	abstract[11]	new[11]	_	_
3-27	172-188	biopharmaceutics	abstract|abstract[11]	new|new[11]	_	_
3-28	189-203	classification	abstract|abstract[11]	new|new[11]	_	_
3-29	204-210	system	abstract[11]	new[11]	_	_
3-30	211-212	(	_	_	_	_
3-31	213-217	pBCS	abstract	giv	coref	4-23[25_0]
3-32	218-219	)	_	_	_	_
3-33	220-223	for	_	_	_	_
3-34	224-228	oral	substance[13]	new[13]	coref	5-5[28_13]
3-35	229-234	drugs	substance[13]	new[13]	_	_
3-36	235-238	and	_	_	_	_
3-37	239-241	to	_	_	_	_
3-38	242-249	compare	_	_	_	_
3-39	250-253	our	person|abstract[15]	acc|new[15]	_	_
3-40	254-261	results	abstract[15]	new[15]	_	_
3-41	262-266	with	abstract[15]	new[15]	_	_
3-42	267-270	the	abstract[15]|abstract[16]	new[15]|new[16]	_	_
3-43	271-274	BCS	abstract[15]|abstract[16]	new[15]|new[16]	_	_
3-44	275-278	for	abstract[15]|abstract[16]	new[15]|new[16]	_	_
3-45	279-285	adults	abstract[15]|abstract[16]|person	new[15]|new[16]|new	coref	9-17
3-46	286-287	(	_	_	_	_
3-47	288-292	aBCS	abstract	new	_	_
3-48	293-294	)	_	_	_	_
3-49	295-296	.	_	_	_	_

#Text=Since 2007 , the WHO has provided the WHO Model List of Essential Medicines for Children ; a core drug list for a basic health-care system .
4-1	297-302	Since	_	_	_	_
4-2	303-307	2007	time	new	_	_
4-3	308-309	,	_	_	_	_
4-4	310-313	the	_	_	_	_
4-5	314-317	WHO	_	_	_	_
4-6	318-321	has	_	_	_	_
4-7	322-330	provided	_	_	_	_
4-8	331-334	the	object[20]	giv[20]	_	_
4-9	335-338	WHO	object[20]	giv[20]	_	_
4-10	339-344	Model	object[20]	giv[20]	_	_
4-11	345-349	List	object[20]	giv[20]	_	_
4-12	350-352	of	object[20]	giv[20]	_	_
4-13	353-362	Essential	object[20]|quantity[21]	giv[20]|giv[21]	_	_
4-14	363-372	Medicines	object[20]|quantity[21]	giv[20]|giv[21]	_	_
4-15	373-376	for	object[20]|quantity[21]	giv[20]|giv[21]	_	_
4-16	377-385	Children	object[20]|quantity[21]|person	giv[20]|giv[21]|giv	coref	22-1
4-17	386-387	;	_	_	_	_
4-18	388-389	a	object[24]	new[24]	coref	5-1[27_24]
4-19	390-394	core	object[24]	new[24]	_	_
4-20	395-399	drug	substance|object[24]	new|new[24]	coref	10-14
4-21	400-404	list	object[24]	new[24]	_	_
4-22	405-408	for	object[24]	new[24]	_	_
4-23	409-410	a	object[24]|abstract[25]	new[24]|giv[25]	_	_
4-24	411-416	basic	object[24]|abstract[25]	new[24]|giv[25]	_	_
4-25	417-428	health-care	object[24]|abstract[25]	new[24]|giv[25]	_	_
4-26	429-435	system	object[24]|abstract[25]	new[24]|giv[25]	_	_
4-27	436-437	.	_	_	_	_

#Text=This resource list considers the safest , efficacious and cost-effective drugs for priority pathologies in pediatrics up to 12 years old .
5-1	438-442	This	object[27]	giv[27]	coref	6-11[35_27]
5-2	443-451	resource	abstract|object[27]	new|giv[27]	_	_
5-3	452-456	list	object[27]	giv[27]	_	_
5-4	457-466	considers	_	_	_	_
5-5	467-470	the	substance[28]	giv[28]	coref	6-4[33_28]
5-6	471-477	safest	substance[28]	giv[28]	_	_
5-7	478-479	,	substance[28]	giv[28]	_	_
5-8	480-491	efficacious	substance[28]	giv[28]	_	_
5-9	492-495	and	substance[28]	giv[28]	_	_
5-10	496-510	cost-effective	substance[28]	giv[28]	_	_
5-11	511-516	drugs	substance[28]	giv[28]	_	_
5-12	517-520	for	substance[28]	giv[28]	_	_
5-13	521-529	priority	substance[28]|abstract[29]	giv[28]|new[29]	_	_
5-14	530-541	pathologies	substance[28]|abstract[29]	giv[28]|new[29]	_	_
5-15	542-544	in	substance[28]|abstract[29]	giv[28]|new[29]	_	_
5-16	545-555	pediatrics	substance[28]|abstract[29]|person[30]	giv[28]|new[29]|new[30]	coref	10-2[52_30]
5-17	556-558	up	substance[28]|abstract[29]|person[30]	giv[28]|new[29]|new[30]	_	_
5-18	559-561	to	_	_	_	_
5-19	562-564	12	time[31]	new[31]	_	_
5-20	565-570	years	time[31]	new[31]	_	_
5-21	571-574	old	_	_	_	_
5-22	575-576	.	_	_	_	_

#Text=All immediate release oral drugs from the sixth edition of this list were selected for this work .
6-1	577-580	All	event[32]	new[32]	_	_
6-2	581-590	immediate	event[32]	new[32]	_	_
6-3	591-598	release	event[32]	new[32]	_	_
6-4	599-603	oral	substance[33]	giv[33]	coref	9-23[48_33]
6-5	604-609	drugs	substance[33]	giv[33]	_	_
6-6	610-614	from	substance[33]	giv[33]	_	_
6-7	615-618	the	substance[33]|abstract[34]	giv[33]|new[34]	_	_
6-8	619-624	sixth	substance[33]|abstract[34]	giv[33]|new[34]	_	_
6-9	625-632	edition	substance[33]|abstract[34]	giv[33]|new[34]	_	_
6-10	633-635	of	substance[33]|abstract[34]	giv[33]|new[34]	_	_
6-11	636-640	this	substance[33]|abstract[34]|object[35]	giv[33]|new[34]|giv[35]	_	_
6-12	641-645	list	substance[33]|abstract[34]|object[35]	giv[33]|new[34]|giv[35]	_	_
6-13	646-650	were	_	_	_	_
6-14	651-659	selected	_	_	_	_
6-15	660-663	for	_	_	_	_
6-16	664-668	this	abstract[36]	new[36]	_	_
6-17	669-673	work	abstract[36]	new[36]	_	_
6-18	674-675	.	_	_	_	_

#Text=The need for and importance of developing appropriate , safe and effective medicines for pediatrics have now been recognized .
7-1	676-679	The	abstract[37]	new[37]	coref	25-1[167_37]
7-2	680-684	need	abstract[37]	new[37]	_	_
7-3	685-688	for	_	_	_	_
7-4	689-692	and	_	_	_	_
7-5	693-703	importance	abstract	new	_	_
7-6	704-706	of	_	_	_	_
7-7	707-717	developing	_	_	_	_
7-8	718-729	appropriate	abstract[39]	new[39]	coref	25-5[168_39]
7-9	730-731	,	abstract[39]	new[39]	_	_
7-10	732-736	safe	abstract[39]	new[39]	_	_
7-11	737-740	and	abstract[39]	new[39]	_	_
7-12	741-750	effective	abstract[39]	new[39]	_	_
7-13	751-760	medicines	abstract[39]	new[39]	_	_
7-14	761-764	for	abstract[39]	new[39]	_	_
7-15	765-775	pediatrics	abstract[39]|abstract	new[39]|new	_	_
7-16	776-780	have	_	_	_	_
7-17	781-784	now	_	_	_	_
7-18	785-789	been	_	_	_	_
7-19	790-800	recognized	_	_	_	_
7-20	801-802	.	_	_	_	_

#Text=Pediatrics have long been considered as a therapeutically disregarded group .
8-1	803-813	Pediatrics	abstract	new	coref	21-14[147_0]
8-2	814-818	have	_	_	_	_
8-3	819-823	long	_	_	_	_
8-4	824-828	been	_	_	_	_
8-5	829-839	considered	_	_	_	_
8-6	840-842	as	_	_	_	_
8-7	843-844	a	_	_	_	_
8-8	845-860	therapeutically	_	_	_	_
8-9	861-872	disregarded	_	_	_	_
8-10	873-878	group	_	_	_	_
8-11	879-880	.	_	_	_	_

#Text=This fact lies in the therapeutic gap that originates from formulation development ( mainly focused on adults ) , low availability of commercial pediatric drugs for pediatric use and physiological and anatomical differences relative to the adult population .
9-1	881-885	This	abstract[42]	new[42]	_	_
9-2	886-890	fact	abstract[42]	new[42]	_	_
9-3	891-895	lies	_	_	_	_
9-4	896-898	in	_	_	_	_
9-5	899-902	the	abstract[43]	new[43]	_	_
9-6	903-914	therapeutic	abstract[43]	new[43]	_	_
9-7	915-918	gap	abstract[43]	new[43]	_	_
9-8	919-923	that	_	_	_	_
9-9	924-934	originates	_	_	_	_
9-10	935-939	from	_	_	_	_
9-11	940-951	formulation	abstract|abstract[45]	new|new[45]	coref|coref	26-47[181_0]|26-47[181_0]
9-12	952-963	development	abstract[45]	new[45]	_	_
9-13	964-965	(	_	_	_	_
9-14	966-972	mainly	_	_	_	_
9-15	973-980	focused	_	_	_	_
9-16	981-983	on	_	_	_	_
9-17	984-990	adults	person	giv	coref	10-22
9-18	991-992	)	_	_	_	_
9-19	993-994	,	_	_	_	_
9-20	995-998	low	abstract[47]	new[47]	_	_
9-21	999-1011	availability	abstract[47]	new[47]	_	_
9-22	1012-1014	of	abstract[47]	new[47]	_	_
9-23	1015-1025	commercial	abstract[47]|substance[48]	new[47]|giv[48]	coref	11-31[0_48]
9-24	1026-1035	pediatric	abstract[47]|substance[48]	new[47]|giv[48]	_	_
9-25	1036-1041	drugs	abstract[47]|substance[48]	new[47]|giv[48]	_	_
9-26	1042-1045	for	abstract[47]|substance[48]	new[47]|giv[48]	_	_
9-27	1046-1055	pediatric	abstract[47]|substance[48]|abstract[49]	new[47]|giv[48]|new[49]	_	_
9-28	1056-1059	use	abstract[47]|substance[48]|abstract[49]	new[47]|giv[48]|new[49]	_	_
9-29	1060-1063	and	abstract[47]|substance[48]	new[47]|giv[48]	_	_
9-30	1064-1077	physiological	abstract[47]|substance[48]|abstract[50]	new[47]|giv[48]|new[50]	coref	11-1[59_50]
9-31	1078-1081	and	abstract[47]|substance[48]|abstract[50]	new[47]|giv[48]|new[50]	_	_
9-32	1082-1092	anatomical	abstract[47]|substance[48]|abstract[50]	new[47]|giv[48]|new[50]	_	_
9-33	1093-1104	differences	abstract[47]|substance[48]|abstract[50]	new[47]|giv[48]|new[50]	_	_
9-34	1105-1113	relative	abstract[47]|substance[48]|abstract[50]	new[47]|giv[48]|new[50]	_	_
9-35	1114-1116	to	_	_	_	_
9-36	1117-1120	the	person[51]	new[51]	_	_
9-37	1121-1126	adult	person[51]	new[51]	_	_
9-38	1127-1137	population	person[51]	new[51]	_	_
9-39	1138-1139	.	_	_	_	_

#Text=In younger pediatrics , neonates and infants , the therapeutic-risk benefits associated with drug treatment may be different from those in adults .
10-1	1140-1142	In	_	_	_	_
10-2	1143-1150	younger	person[52]	giv[52]	_	_
10-3	1151-1161	pediatrics	person[52]	giv[52]	_	_
10-4	1162-1163	,	_	_	_	_
10-5	1164-1172	neonates	person	new	coref	18-6
10-6	1173-1176	and	_	_	_	_
10-7	1177-1184	infants	person	new	_	_
10-8	1185-1186	,	_	_	_	_
10-9	1187-1190	the	abstract[55]	new[55]	_	_
10-10	1191-1207	therapeutic-risk	abstract[55]	new[55]	_	_
10-11	1208-1216	benefits	abstract[55]	new[55]	_	_
10-12	1217-1227	associated	_	_	_	_
10-13	1228-1232	with	_	_	_	_
10-14	1233-1237	drug	substance|abstract[57]	giv|new[57]	coref|coref	11-18|11-18
10-15	1238-1247	treatment	abstract[57]	new[57]	_	_
10-16	1248-1251	may	_	_	_	_
10-17	1252-1254	be	_	_	_	_
10-18	1255-1264	different	_	_	_	_
10-19	1265-1269	from	_	_	_	_
10-20	1270-1275	those	_	_	_	_
10-21	1276-1278	in	_	_	_	_
10-22	1279-1285	adults	person	giv	coref	15-16[103_0]
10-23	1286-1287	.	_	_	_	_

#Text=Developmental physiological differences ( as the composition of gastrointestinal fluids and the presence or activity of intestinal drug metabolizing enzymes and efflux transporters ) can markedly alter the bioavailability of drugs .
11-1	1288-1301	Developmental	abstract[59]	giv[59]	coref	20-5[138_59]
11-2	1302-1315	physiological	abstract[59]	giv[59]	_	_
11-3	1316-1327	differences	abstract[59]	giv[59]	_	_
11-4	1328-1329	(	abstract[59]	giv[59]	_	_
11-5	1330-1332	as	abstract[59]	giv[59]	_	_
11-6	1333-1336	the	abstract[59]	giv[59]	_	_
11-7	1337-1348	composition	abstract[59]	giv[59]	_	_
11-8	1349-1351	of	abstract[59]	giv[59]	_	_
11-9	1352-1368	gastrointestinal	abstract[59]|substance[60]	giv[59]|new[60]	coref	12-7[73_60]
11-10	1369-1375	fluids	abstract[59]|substance[60]	giv[59]|new[60]	_	_
11-11	1376-1379	and	abstract[59]	giv[59]	_	_
11-12	1380-1383	the	abstract[59]|abstract[61]	giv[59]|new[61]	_	_
11-13	1384-1392	presence	abstract[59]|abstract[61]	giv[59]|new[61]	_	_
11-14	1393-1395	or	abstract[59]	giv[59]	_	_
11-15	1396-1404	activity	abstract[59]|abstract	giv[59]|new	coref	17-10
11-16	1405-1407	of	abstract[59]	giv[59]	_	_
11-17	1408-1418	intestinal	abstract[59]|substance[65]|abstract[66]	giv[59]|new[65]|new[66]	coref|coref|coref|coref	16-17[112_65]|16-17[113_66]|16-17[112_65]|16-17[113_66]
11-18	1419-1423	drug	abstract[59]|substance|substance[65]|abstract[66]	giv[59]|giv|new[65]|new[66]	coref	12-17
11-19	1424-1436	metabolizing	abstract[59]|abstract|substance[65]|abstract[66]	giv[59]|new|new[65]|new[66]	coref	16-18
11-20	1437-1444	enzymes	abstract[59]|substance[65]|abstract[66]	giv[59]|new[65]|new[66]	_	_
11-21	1445-1448	and	abstract[59]|abstract[66]	giv[59]|new[66]	_	_
11-22	1449-1455	efflux	abstract[59]|abstract[66]|abstract|person[68]	giv[59]|new[66]|new|new[68]	coref|coref|coref|coref	16-21[0_68]|20-15|16-21[0_68]|20-15
11-23	1456-1468	transporters	abstract[59]|abstract[66]|person[68]	giv[59]|new[66]|new[68]	_	_
11-24	1469-1470	)	abstract[59]	giv[59]	_	_
11-25	1471-1474	can	_	_	_	_
11-26	1475-1483	markedly	_	_	_	_
11-27	1484-1489	alter	_	_	_	_
11-28	1490-1493	the	abstract[69]	new[69]	coref	16-9[0_69]
11-29	1494-1509	bioavailability	abstract[69]	new[69]	_	_
11-30	1510-1512	of	abstract[69]	new[69]	_	_
11-31	1513-1518	drugs	abstract[69]|substance	new[69]|giv	coref	13-7[83_0]
11-32	1519-1520	.	_	_	_	_

#Text=Age-related changes in the characteristics of luminal fluids such as pH may lead to changes in drug solubility and , therefore , in absorption since only the dissolved drug would be available for absorption .
12-1	1521-1532	Age-related	abstract[71]	new[71]	_	_
12-2	1533-1540	changes	abstract[71]	new[71]	_	_
12-3	1541-1543	in	abstract[71]	new[71]	_	_
12-4	1544-1547	the	abstract[71]|abstract[72]	new[71]|new[72]	_	_
12-5	1548-1563	characteristics	abstract[71]|abstract[72]	new[71]|new[72]	_	_
12-6	1564-1566	of	abstract[71]|abstract[72]	new[71]|new[72]	_	_
12-7	1567-1574	luminal	abstract[71]|abstract[72]|substance[73]	new[71]|new[72]|giv[73]	_	_
12-8	1575-1581	fluids	abstract[71]|abstract[72]|substance[73]	new[71]|new[72]|giv[73]	_	_
12-9	1582-1586	such	abstract[71]|abstract[72]|substance[73]	new[71]|new[72]|giv[73]	_	_
12-10	1587-1589	as	abstract[71]|abstract[72]|substance[73]	new[71]|new[72]|giv[73]	_	_
12-11	1590-1592	pH	abstract[71]|abstract[72]|substance[73]|abstract	new[71]|new[72]|giv[73]|new	coref	13-4
12-12	1593-1596	may	_	_	_	_
12-13	1597-1601	lead	_	_	_	_
12-14	1602-1604	to	_	_	_	_
12-15	1605-1612	changes	abstract[75]	new[75]	coref	13-21[86_75]
12-16	1613-1615	in	abstract[75]	new[75]	_	_
12-17	1616-1620	drug	abstract[75]|substance|abstract[77]	new[75]|giv|new[77]	coref|coref	12-27[79_0]|12-27[79_0]
12-18	1621-1631	solubility	abstract[75]|abstract[77]	new[75]|new[77]	_	_
12-19	1632-1635	and	_	_	_	_
12-20	1636-1637	,	_	_	_	_
12-21	1638-1647	therefore	_	_	_	_
12-22	1648-1649	,	_	_	_	_
12-23	1650-1652	in	_	_	_	_
12-24	1653-1663	absorption	event	new	_	_
12-25	1664-1669	since	_	_	_	_
12-26	1670-1674	only	_	_	_	_
12-27	1675-1678	the	substance[79]	giv[79]	coref	13-14[85_79]
12-28	1679-1688	dissolved	substance[79]	giv[79]	_	_
12-29	1689-1693	drug	substance[79]	giv[79]	_	_
12-30	1694-1699	would	_	_	_	_
12-31	1700-1702	be	_	_	_	_
12-32	1703-1712	available	_	_	_	_
12-33	1713-1716	for	_	_	_	_
12-34	1717-1727	absorption	event	new	coref	13-23[87_0]
12-35	1728-1729	.	_	_	_	_

#Text=Since fluctuations in pH may influence ionizable drugs and the relative amount of unionized available drug , there could be changes in absorption during maturation .
13-1	1730-1735	Since	_	_	_	_
13-2	1736-1748	fluctuations	abstract[81]	new[81]	_	_
13-3	1749-1751	in	abstract[81]	new[81]	_	_
13-4	1752-1754	pH	abstract[81]|abstract	new[81]|giv	coref	14-1[89_0]
13-5	1755-1758	may	_	_	_	_
13-6	1759-1768	influence	_	_	_	_
13-7	1769-1778	ionizable	substance[83]	giv[83]	coref	21-1[146_83]
13-8	1779-1784	drugs	substance[83]	giv[83]	_	_
13-9	1785-1788	and	substance[83]	giv[83]	_	_
13-10	1789-1792	the	substance[83]|quantity[84]	giv[83]|new[84]	_	_
13-11	1793-1801	relative	substance[83]|quantity[84]	giv[83]|new[84]	_	_
13-12	1802-1808	amount	substance[83]|quantity[84]	giv[83]|new[84]	_	_
13-13	1809-1811	of	substance[83]|quantity[84]	giv[83]|new[84]	_	_
13-14	1812-1821	unionized	substance[83]|quantity[84]|substance[85]	giv[83]|new[84]|giv[85]	coref	16-17[0_85]
13-15	1822-1831	available	substance[83]|quantity[84]|substance[85]	giv[83]|new[84]|giv[85]	_	_
13-16	1832-1836	drug	substance[83]|quantity[84]|substance[85]	giv[83]|new[84]|giv[85]	_	_
13-17	1837-1838	,	_	_	_	_
13-18	1839-1844	there	_	_	_	_
13-19	1845-1850	could	_	_	_	_
13-20	1851-1853	be	_	_	_	_
13-21	1854-1861	changes	abstract[86]	giv[86]	_	_
13-22	1862-1864	in	abstract[86]	giv[86]	_	_
13-23	1865-1875	absorption	abstract[86]|event[87]	giv[86]|giv[87]	_	_
13-24	1876-1882	during	abstract[86]|event[87]	giv[86]|giv[87]	_	_
13-25	1883-1893	maturation	abstract[86]|event[87]|event	giv[86]|giv[87]|new	_	_
13-26	1894-1895	.	_	_	_	_

#Text=The gastric pH of the newborn is approximately neutral , and within the first 48 h of life , the gastrointestinal pH decreases to adult values and then for the first month increases back to values close to neutrality .
14-1	1896-1899	The	abstract[89]	giv[89]	coref	14-20[93_89]
14-2	1900-1907	gastric	abstract[89]	giv[89]	_	_
14-3	1908-1910	pH	abstract[89]	giv[89]	_	_
14-4	1911-1913	of	abstract[89]	giv[89]	_	_
14-5	1914-1917	the	abstract[89]|person[90]	giv[89]|new[90]	_	_
14-6	1918-1925	newborn	abstract[89]|person[90]	giv[89]|new[90]	_	_
14-7	1926-1928	is	_	_	_	_
14-8	1929-1942	approximately	_	_	_	_
14-9	1943-1950	neutral	_	_	_	_
14-10	1951-1952	,	_	_	_	_
14-11	1953-1956	and	_	_	_	_
14-12	1957-1963	within	_	_	_	_
14-13	1964-1967	the	time[91]	new[91]	_	_
14-14	1968-1973	first	time[91]	new[91]	_	_
14-15	1974-1976	48	time[91]	new[91]	_	_
14-16	1977-1978	h	time[91]	new[91]	_	_
14-17	1979-1981	of	time[91]	new[91]	_	_
14-18	1982-1986	life	time[91]|time	new[91]|new	coref	20-22
14-19	1987-1988	,	_	_	_	_
14-20	1989-1992	the	abstract[93]	giv[93]	coref	15-6[101_93]
14-21	1993-2009	gastrointestinal	abstract[93]	giv[93]	_	_
14-22	2010-2012	pH	abstract[93]	giv[93]	_	_
14-23	2013-2022	decreases	_	_	_	_
14-24	2023-2025	to	_	_	_	_
14-25	2026-2031	adult	abstract[94]	new[94]	coref	14-36[97_94]
14-26	2032-2038	values	abstract[94]	new[94]	_	_
14-27	2039-2042	and	_	_	_	_
14-28	2043-2047	then	_	_	_	_
14-29	2048-2051	for	_	_	_	_
14-30	2052-2055	the	event[96]	new[96]	_	_
14-31	2056-2061	first	event[96]	new[96]	_	_
14-32	2062-2067	month	time|event[96]	new|new[96]	_	_
14-33	2068-2077	increases	event[96]	new[96]	_	_
14-34	2078-2082	back	event[96]	new[96]	_	_
14-35	2083-2085	to	event[96]	new[96]	_	_
14-36	2086-2092	values	event[96]|abstract[97]	new[96]|giv[97]	coref	15-12[102_97]
14-37	2093-2098	close	event[96]|abstract[97]	new[96]|giv[97]	_	_
14-38	2099-2101	to	_	_	_	_
14-39	2102-2112	neutrality	abstract	new	_	_
14-40	2113-2114	.	_	_	_	_

#Text=After the first month , gastric pH decreases progressively to reach similar values as in adults by two years of age .
15-1	2115-2120	After	_	_	_	_
15-2	2121-2124	the	time[99]	new[99]	_	_
15-3	2125-2130	first	time[99]	new[99]	_	_
15-4	2131-2136	month	time[99]	new[99]	_	_
15-5	2137-2138	,	_	_	_	_
15-6	2139-2146	gastric	abstract|abstract[101]	new|giv[101]	_	_
15-7	2147-2149	pH	abstract[101]	giv[101]	_	_
15-8	2150-2159	decreases	_	_	_	_
15-9	2160-2173	progressively	_	_	_	_
15-10	2174-2176	to	_	_	_	_
15-11	2177-2182	reach	_	_	_	_
15-12	2183-2190	similar	abstract[102]	giv[102]	_	_
15-13	2191-2197	values	abstract[102]	giv[102]	_	_
15-14	2198-2200	as	_	_	_	_
15-15	2201-2203	in	_	_	_	_
15-16	2204-2210	adults	person[103]	giv[103]	coref	20-24[0_103]
15-17	2211-2213	by	person[103]	giv[103]	_	_
15-18	2214-2217	two	person[103]|time[104]	giv[103]|new[104]	coref	18-20[129_104]
15-19	2218-2223	years	person[103]|time[104]	giv[103]|new[104]	_	_
15-20	2224-2226	of	person[103]|time[104]	giv[103]|new[104]	_	_
15-21	2227-2230	age	person[103]|time[104]|abstract	giv[103]|new[104]|new	coref	17-12
15-22	2231-2232	.	_	_	_	_

#Text=On the other hand , another determinant of bioavailability is ontogenic changes in the expression of drug metabolizing enzymes and transporters , which would mark the first pass effect and consequently would change the oral absorbed fraction .
16-1	2233-2235	On	_	_	_	_
16-2	2236-2239	the	_	_	_	_
16-3	2240-2245	other	_	_	_	_
16-4	2246-2250	hand	_	_	_	_
16-5	2251-2252	,	_	_	_	_
16-6	2253-2260	another	abstract[106]	new[106]	coref	16-11[108_106]
16-7	2261-2272	determinant	abstract[106]	new[106]	_	_
16-8	2273-2275	of	abstract[106]	new[106]	_	_
16-9	2276-2291	bioavailability	abstract[106]|abstract	new[106]|giv	_	_
16-10	2292-2294	is	_	_	_	_
16-11	2295-2304	ontogenic	abstract[108]	giv[108]	_	_
16-12	2305-2312	changes	abstract[108]	giv[108]	_	_
16-13	2313-2315	in	abstract[108]	giv[108]	_	_
16-14	2316-2319	the	abstract[108]|abstract[109]	giv[108]|new[109]	coref	17-8[0_109]
16-15	2320-2330	expression	abstract[108]|abstract[109]	giv[108]|new[109]	_	_
16-16	2331-2333	of	abstract[108]|abstract[109]	giv[108]|new[109]	_	_
16-17	2334-2338	drug	abstract[108]|abstract[109]|substance|substance[112]|abstract[113]	giv[108]|new[109]|giv|giv[112]|giv[113]	coref|coref|coref	19-17[136_112]|19-17[136_112]|19-17[136_112]
16-18	2339-2351	metabolizing	abstract[108]|abstract[109]|abstract|substance[112]|abstract[113]	giv[108]|new[109]|giv|giv[112]|giv[113]	_	_
16-19	2352-2359	enzymes	abstract[108]|abstract[109]|substance[112]|abstract[113]	giv[108]|new[109]|giv[112]|giv[113]	_	_
16-20	2360-2363	and	abstract[108]|abstract[109]|abstract[113]	giv[108]|new[109]|giv[113]	_	_
16-21	2364-2376	transporters	abstract[108]|abstract[109]|abstract[113]|person	giv[108]|new[109]|giv[113]|giv	_	_
16-22	2377-2378	,	_	_	_	_
16-23	2379-2384	which	_	_	_	_
16-24	2385-2390	would	_	_	_	_
16-25	2391-2395	mark	_	_	_	_
16-26	2396-2399	the	abstract[116]	new[116]	coref	27-56[202_116]
16-27	2400-2405	first	abstract[116]	new[116]	_	_
16-28	2406-2410	pass	abstract|abstract[116]	new|new[116]	_	_
16-29	2411-2417	effect	abstract[116]	new[116]	_	_
16-30	2418-2421	and	_	_	_	_
16-31	2422-2434	consequently	_	_	_	_
16-32	2435-2440	would	_	_	_	_
16-33	2441-2447	change	_	_	_	_
16-34	2448-2451	the	abstract[117]	new[117]	_	_
16-35	2452-2456	oral	abstract[117]	new[117]	_	_
16-36	2457-2465	absorbed	abstract[117]	new[117]	_	_
16-37	2466-2474	fraction	abstract[117]	new[117]	_	_
16-38	2475-2476	.	_	_	_	_

#Text=For example , the CYP3A4 isoenzyme increases expression and activity with age .
17-1	2477-2480	For	_	_	_	_
17-2	2481-2488	example	_	_	_	_
17-3	2489-2490	,	_	_	_	_
17-4	2491-2494	the	abstract[119]	new[119]	_	_
17-5	2495-2501	CYP3A4	abstract|abstract[119]	new|new[119]	coref	18-1
17-6	2502-2511	isoenzyme	abstract[119]	new[119]	_	_
17-7	2512-2521	increases	_	_	_	_
17-8	2522-2532	expression	abstract	giv	coref	18-9[126_0]
17-9	2533-2536	and	_	_	_	_
17-10	2537-2545	activity	abstract	giv	coref	19-10[133_0]
17-11	2546-2550	with	_	_	_	_
17-12	2551-2554	age	abstract	giv	coref	18-13
17-13	2555-2556	.	_	_	_	_

#Text=CYP3A4 is practically undetectable in neonates , and its expression increases with age , reaching a maximum level at two years of age .
18-1	2557-2563	CYP3A4	abstract	giv	ana	18-9
18-2	2564-2566	is	_	_	_	_
18-3	2567-2578	practically	_	_	_	_
18-4	2579-2591	undetectable	_	_	_	_
18-5	2592-2594	in	_	_	_	_
18-6	2595-2603	neonates	abstract	giv	_	_
18-7	2604-2605	,	_	_	_	_
18-8	2606-2609	and	_	_	_	_
18-9	2610-2613	its	abstract|abstract[126]	giv|giv[126]	coref|coref	20-8[140_126]|20-8[140_126]
18-10	2614-2624	expression	abstract[126]	giv[126]	_	_
18-11	2625-2634	increases	_	_	_	_
18-12	2635-2639	with	_	_	_	_
18-13	2640-2643	age	abstract	giv	coref	18-23
18-14	2644-2645	,	_	_	_	_
18-15	2646-2654	reaching	_	_	_	_
18-16	2655-2656	a	abstract[128]	new[128]	_	_
18-17	2657-2664	maximum	abstract[128]	new[128]	_	_
18-18	2665-2670	level	abstract[128]	new[128]	_	_
18-19	2671-2673	at	_	_	_	_
18-20	2674-2677	two	time[129]	giv[129]	_	_
18-21	2678-2683	years	time[129]	giv[129]	_	_
18-22	2684-2686	of	time[129]	giv[129]	_	_
18-23	2687-2690	age	time[129]|abstract	giv[129]|giv	coref	19-5
18-24	2691-2692	.	_	_	_	_

#Text=Likewise , in these age groups , there is immature intestinal activity of alkaline phosphatase , glucuronidation enzymes and carboxylesterase-2 .
19-1	2693-2701	Likewise	_	_	_	_
19-2	2702-2703	,	_	_	_	_
19-3	2704-2706	in	_	_	_	_
19-4	2707-2712	these	person[132]	new[132]	coref	26-36[179_132]
19-5	2713-2716	age	abstract|person[132]	giv|new[132]	coref	26-21
19-6	2717-2723	groups	person[132]	new[132]	_	_
19-7	2724-2725	,	_	_	_	_
19-8	2726-2731	there	_	_	_	_
19-9	2732-2734	is	_	_	_	_
19-10	2735-2743	immature	abstract[133]	giv[133]	_	_
19-11	2744-2754	intestinal	abstract[133]	giv[133]	_	_
19-12	2755-2763	activity	abstract[133]	giv[133]	_	_
19-13	2764-2766	of	abstract[133]	giv[133]	_	_
19-14	2767-2775	alkaline	abstract[133]|substance[134]	giv[133]|new[134]	_	_
19-15	2776-2787	phosphatase	abstract[133]|substance[134]	giv[133]|new[134]	_	_
19-16	2788-2789	,	abstract[133]	giv[133]	_	_
19-17	2790-2805	glucuronidation	abstract[133]|abstract|substance[136]	giv[133]|new|giv[136]	_	_
19-18	2806-2813	enzymes	abstract[133]|substance[136]	giv[133]|giv[136]	_	_
19-19	2814-2817	and	abstract[133]	giv[133]	_	_
19-20	2818-2836	carboxylesterase-2	abstract[133]|substance	giv[133]|new	_	_
19-21	2837-2838	.	_	_	_	_

#Text=Conversely , there are no differences in p-glycoprotein expression , the most studied intestinal efflux transporter from the earliest stages of life to adults .
20-1	2839-2849	Conversely	_	_	_	_
20-2	2850-2851	,	_	_	_	_
20-3	2852-2857	there	_	_	_	_
20-4	2858-2861	are	_	_	_	_
20-5	2862-2864	no	abstract[138]	giv[138]	_	_
20-6	2865-2876	differences	abstract[138]	giv[138]	_	_
20-7	2877-2879	in	abstract[138]	giv[138]	_	_
20-8	2880-2894	p-glycoprotein	abstract[138]|person|abstract[140]	giv[138]|new|giv[140]	_	_
20-9	2895-2905	expression	abstract[138]|abstract[140]	giv[138]|giv[140]	_	_
20-10	2906-2907	,	abstract[138]	giv[138]	_	_
20-11	2908-2911	the	abstract[138]|abstract[142]	giv[138]|new[142]	_	_
20-12	2912-2916	most	abstract[138]|abstract[142]	giv[138]|new[142]	_	_
20-13	2917-2924	studied	abstract[138]|abstract[142]	giv[138]|new[142]	_	_
20-14	2925-2935	intestinal	abstract[138]|abstract[142]	giv[138]|new[142]	_	_
20-15	2936-2942	efflux	abstract[138]|abstract|abstract[142]	giv[138]|giv|new[142]	_	_
20-16	2943-2954	transporter	abstract[138]|abstract[142]	giv[138]|new[142]	_	_
20-17	2955-2959	from	abstract[138]|abstract[142]	giv[138]|new[142]	_	_
20-18	2960-2963	the	abstract[138]|abstract[142]|abstract[143]	giv[138]|new[142]|new[143]	_	_
20-19	2964-2972	earliest	abstract[138]|abstract[142]|abstract[143]	giv[138]|new[142]|new[143]	_	_
20-20	2973-2979	stages	abstract[138]|abstract[142]|abstract[143]	giv[138]|new[142]|new[143]	_	_
20-21	2980-2982	of	abstract[138]|abstract[142]|abstract[143]	giv[138]|new[142]|new[143]	_	_
20-22	2983-2987	life	abstract[138]|abstract[142]|abstract[143]|abstract	giv[138]|new[142]|new[143]|giv	_	_
20-23	2988-2990	to	abstract[138]|abstract[142]|abstract[143]	giv[138]|new[142]|new[143]	_	_
20-24	2991-2997	adults	abstract[138]|abstract[142]|abstract[143]|person	giv[138]|new[142]|new[143]|giv	coref	22-8
20-25	2998-2999	.	_	_	_	_

#Text=Many drugs are formulated as pharmaceutical forms that are often not appropriate for pediatrics , such as tablets or capsules .
21-1	3000-3004	Many	substance[146]	giv[146]	_	_
21-2	3005-3010	drugs	substance[146]	giv[146]	_	_
21-3	3011-3014	are	_	_	_	_
21-4	3015-3025	formulated	_	_	_	_
21-5	3026-3028	as	_	_	_	_
21-6	3029-3043	pharmaceutical	_	_	_	_
21-7	3044-3049	forms	_	_	_	_
21-8	3050-3054	that	_	_	_	_
21-9	3055-3058	are	_	_	_	_
21-10	3059-3064	often	_	_	_	_
21-11	3065-3068	not	_	_	_	_
21-12	3069-3080	appropriate	_	_	_	_
21-13	3081-3084	for	_	_	_	_
21-14	3085-3095	pediatrics	abstract[147]	giv[147]	coref	23-1[160_147]
21-15	3096-3097	,	abstract[147]	giv[147]	_	_
21-16	3098-3102	such	abstract[147]	giv[147]	_	_
21-17	3103-3105	as	abstract[147]	giv[147]	_	_
21-18	3106-3113	tablets	abstract[147]|object	giv[147]|new	_	_
21-19	3114-3116	or	abstract[147]	giv[147]	_	_
21-20	3117-3125	capsules	abstract[147]|object	giv[147]|new	_	_
21-21	3126-3127	.	_	_	_	_

#Text=Children need different oral dosage formulations from adults mainly due to their developmental capabilities in swallowing ability , palatability and dosage requirements .
22-1	3128-3136	Children	person	giv	coref	27-59
22-2	3137-3141	need	_	_	_	_
22-3	3142-3151	different	abstract[152]	new[152]	coref	25-13[170_152]
22-4	3152-3156	oral	abstract[152]	new[152]	_	_
22-5	3157-3163	dosage	substance|abstract[152]	new|new[152]	coref	22-21
22-6	3164-3176	formulations	abstract[152]	new[152]	_	_
22-7	3177-3181	from	abstract[152]	new[152]	_	_
22-8	3182-3188	adults	abstract[152]|person	new[152]|giv	ana	22-12
22-9	3189-3195	mainly	_	_	_	_
22-10	3196-3199	due	_	_	_	_
22-11	3200-3202	to	_	_	_	_
22-12	3203-3208	their	person|abstract[155]	giv|new[155]	_	_
22-13	3209-3222	developmental	abstract[155]	new[155]	_	_
22-14	3223-3235	capabilities	abstract[155]	new[155]	_	_
22-15	3236-3238	in	_	_	_	_
22-16	3239-3249	swallowing	_	_	_	_
22-17	3250-3257	ability	abstract	new	_	_
22-18	3258-3259	,	_	_	_	_
22-19	3260-3272	palatability	abstract	new	coref	23-5
22-20	3273-3276	and	_	_	_	_
22-21	3277-3283	dosage	quantity|abstract[159]	giv|new[159]	_	_
22-22	3284-3296	requirements	abstract[159]	new[159]	_	_
22-23	3297-3298	.	_	_	_	_

#Text=Especially in pediatrics , palatability is closely related to acceptance and adherence .
23-1	3299-3309	Especially	abstract[160]	giv[160]	coref	25-8[0_160]
23-2	3310-3312	in	abstract[160]	giv[160]	_	_
23-3	3313-3323	pediatrics	abstract[160]	giv[160]	_	_
23-4	3324-3325	,	_	_	_	_
23-5	3326-3338	palatability	abstract	giv	_	_
23-6	3339-3341	is	_	_	_	_
23-7	3342-3349	closely	_	_	_	_
23-8	3350-3357	related	_	_	_	_
23-9	3358-3360	to	_	_	_	_
23-10	3361-3371	acceptance	abstract	new	_	_
23-11	3372-3375	and	_	_	_	_
23-12	3376-3385	adherence	abstract	new	_	_
23-13	3386-3387	.	_	_	_	_

#Text=Consequently , bitterness , trigeminal irritation and perceptible malodors must be minimized .
24-1	3388-3400	Consequently	_	_	_	_
24-2	3401-3402	,	_	_	_	_
24-3	3403-3413	bitterness	abstract	new	_	_
24-4	3414-3415	,	_	_	_	_
24-5	3416-3426	trigeminal	abstract[165]	new[165]	_	_
24-6	3427-3437	irritation	abstract[165]	new[165]	_	_
24-7	3438-3441	and	_	_	_	_
24-8	3442-3453	perceptible	abstract[166]	new[166]	_	_
24-9	3454-3462	malodors	abstract[166]	new[166]	_	_
24-10	3463-3467	must	_	_	_	_
24-11	3468-3470	be	_	_	_	_
24-12	3471-3480	minimized	_	_	_	_
24-13	3481-3482	.	_	_	_	_

#Text=The increasing need for age-related medicines in pediatrics could be met by extemporaneous formulations .
25-1	3483-3486	The	abstract[167]	giv[167]	coref	26-57[182_167]
25-2	3487-3497	increasing	abstract[167]	giv[167]	_	_
25-3	3498-3502	need	abstract[167]	giv[167]	_	_
25-4	3503-3506	for	abstract[167]	giv[167]	_	_
25-5	3507-3518	age-related	abstract[167]|substance[168]	giv[167]|giv[168]	coref	28-25[210_168]
25-6	3519-3528	medicines	abstract[167]|substance[168]	giv[167]|giv[168]	_	_
25-7	3529-3531	in	abstract[167]|substance[168]	giv[167]|giv[168]	_	_
25-8	3532-3542	pediatrics	abstract[167]|substance[168]|abstract	giv[167]|giv[168]|giv	coref	28-37
25-9	3543-3548	could	_	_	_	_
25-10	3549-3551	be	_	_	_	_
25-11	3552-3555	met	_	_	_	_
25-12	3556-3558	by	_	_	_	_
25-13	3559-3573	extemporaneous	abstract[170]	giv[170]	coref	27-8[186_170]
25-14	3574-3586	formulations	abstract[170]	giv[170]	_	_
25-15	3587-3588	.	_	_	_	_

#Text=The compounding of an extemporaneous formula is not allowed if an authorized commercial pharmaceutical product ( adequate for a particular age group ) exists , but the reality in the clinical setting is that for some age groups , that is not the case , while extemporaneous formulation is still used as the only alternative to the therapeutic need .
26-1	3589-3592	The	event[171]	new[171]	_	_
26-2	3593-3604	compounding	event[171]	new[171]	_	_
26-3	3605-3607	of	event[171]	new[171]	_	_
26-4	3608-3610	an	event[171]|object[172]	new[171]|new[172]	_	_
26-5	3611-3625	extemporaneous	event[171]|object[172]	new[171]|new[172]	_	_
26-6	3626-3633	formula	event[171]|object[172]	new[171]|new[172]	_	_
26-7	3634-3636	is	_	_	_	_
26-8	3637-3640	not	_	_	_	_
26-9	3641-3648	allowed	_	_	_	_
26-10	3649-3651	if	_	_	_	_
26-11	3652-3654	an	object[173]	new[173]	_	_
26-12	3655-3665	authorized	object[173]	new[173]	_	_
26-13	3666-3676	commercial	object[173]	new[173]	_	_
26-14	3677-3691	pharmaceutical	object[173]	new[173]	_	_
26-15	3692-3699	product	object[173]	new[173]	_	_
26-16	3700-3701	(	_	_	_	_
26-17	3702-3710	adequate	_	_	_	_
26-18	3711-3714	for	_	_	_	_
26-19	3715-3716	a	abstract[175]	new[175]	coref	28-13[208_175]
26-20	3717-3727	particular	abstract[175]	new[175]	_	_
26-21	3728-3731	age	abstract|abstract[175]	giv|new[175]	coref	26-37
26-22	3732-3737	group	abstract[175]	new[175]	_	_
26-23	3738-3739	)	_	_	_	_
26-24	3740-3746	exists	_	_	_	_
26-25	3747-3748	,	_	_	_	_
26-26	3749-3752	but	_	_	_	_
26-27	3753-3756	the	abstract[176]	new[176]	_	_
26-28	3757-3764	reality	abstract[176]	new[176]	_	_
26-29	3765-3767	in	abstract[176]	new[176]	_	_
26-30	3768-3771	the	abstract[176]|abstract[177]	new[176]|new[177]	ana	26-40[0_177]
26-31	3772-3780	clinical	abstract[176]|abstract[177]	new[176]|new[177]	_	_
26-32	3781-3788	setting	abstract[176]|abstract[177]	new[176]|new[177]	_	_
26-33	3789-3791	is	_	_	_	_
26-34	3792-3796	that	_	_	_	_
26-35	3797-3800	for	_	_	_	_
26-36	3801-3805	some	person[179]	giv[179]	_	_
26-37	3806-3809	age	abstract|person[179]	giv|giv[179]	coref	28-14
26-38	3810-3816	groups	person[179]	giv[179]	_	_
26-39	3817-3818	,	_	_	_	_
26-40	3819-3823	that	abstract	giv	_	_
26-41	3824-3826	is	_	_	_	_
26-42	3827-3830	not	_	_	_	_
26-43	3831-3834	the	_	_	_	_
26-44	3835-3839	case	_	_	_	_
26-45	3840-3841	,	_	_	_	_
26-46	3842-3847	while	_	_	_	_
26-47	3848-3862	extemporaneous	abstract[181]	giv[181]	_	_
26-48	3863-3874	formulation	abstract[181]	giv[181]	_	_
26-49	3875-3877	is	_	_	_	_
26-50	3878-3883	still	_	_	_	_
26-51	3884-3888	used	_	_	_	_
26-52	3889-3891	as	_	_	_	_
26-53	3892-3895	the	_	_	_	_
26-54	3896-3900	only	_	_	_	_
26-55	3901-3912	alternative	_	_	_	_
26-56	3913-3915	to	_	_	_	_
26-57	3916-3919	the	abstract[182]	giv[182]	_	_
26-58	3920-3931	therapeutic	abstract[182]	giv[182]	_	_
26-59	3932-3936	need	abstract[182]	giv[182]	_	_
26-60	3937-3938	.	_	_	_	_

#Text=Although solid products have higher stability than liquid formulations , this practice can solve the problem of swallowing capability and dose adjustments , but these manufactured preparations can be a risk to safety , efficacy and quality , because there is little or no information for compatibility between the original medicine and additional excipients or their effect in children .
27-1	3939-3947	Although	_	_	_	_
27-2	3948-3953	solid	object[183]	new[183]	_	_
27-3	3954-3962	products	object[183]	new[183]	_	_
27-4	3963-3967	have	_	_	_	_
27-5	3968-3974	higher	abstract[184]	new[184]	_	_
27-6	3975-3984	stability	abstract[184]	new[184]	_	_
27-7	3985-3989	than	abstract[184]	new[184]	_	_
27-8	3990-3996	liquid	abstract[184]|substance|abstract[186]	new[184]|new|giv[186]	coref|coref	28-5[0_186]|28-5[0_186]
27-9	3997-4009	formulations	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
27-10	4010-4011	,	_	_	_	_
27-11	4012-4016	this	event[187]	new[187]	_	_
27-12	4017-4025	practice	event[187]	new[187]	_	_
27-13	4026-4029	can	_	_	_	_
27-14	4030-4035	solve	_	_	_	_
27-15	4036-4039	the	abstract[188]	new[188]	_	_
27-16	4040-4047	problem	abstract[188]	new[188]	_	_
27-17	4048-4050	of	abstract[188]	new[188]	_	_
27-18	4051-4061	swallowing	abstract[188]|abstract[189]	new[188]|new[189]	_	_
27-19	4062-4072	capability	abstract[188]|abstract[189]	new[188]|new[189]	_	_
27-20	4073-4076	and	abstract[188]	new[188]	_	_
27-21	4077-4081	dose	abstract[188]|quantity|abstract[191]	new[188]|new|new[191]	_	_
27-22	4082-4093	adjustments	abstract[188]|abstract[191]	new[188]|new[191]	_	_
27-23	4094-4095	,	_	_	_	_
27-24	4096-4099	but	_	_	_	_
27-25	4100-4105	these	abstract[192]	new[192]	coref	27-30[193_192]
27-26	4106-4118	manufactured	abstract[192]	new[192]	_	_
27-27	4119-4131	preparations	abstract[192]	new[192]	_	_
27-28	4132-4135	can	_	_	_	_
27-29	4136-4138	be	_	_	_	_
27-30	4139-4140	a	abstract[193]	giv[193]	_	_
27-31	4141-4145	risk	abstract[193]	giv[193]	_	_
27-32	4146-4148	to	abstract[193]	giv[193]	_	_
27-33	4149-4155	safety	abstract[193]|abstract	giv[193]|new	_	_
27-34	4156-4157	,	abstract[193]	giv[193]	_	_
27-35	4158-4166	efficacy	abstract[193]|abstract	giv[193]|new	_	_
27-36	4167-4170	and	abstract[193]	giv[193]	_	_
27-37	4171-4178	quality	abstract[193]|abstract	giv[193]|new	_	_
27-38	4179-4180	,	_	_	_	_
27-39	4181-4188	because	_	_	_	_
27-40	4189-4194	there	_	_	_	_
27-41	4195-4197	is	_	_	_	_
27-42	4198-4204	little	_	_	_	_
27-43	4205-4207	or	_	_	_	_
27-44	4208-4210	no	abstract[197]	new[197]	_	_
27-45	4211-4222	information	abstract[197]	new[197]	_	_
27-46	4223-4226	for	abstract[197]	new[197]	_	_
27-47	4227-4240	compatibility	abstract[197]|abstract[198]	new[197]|new[198]	_	_
27-48	4241-4248	between	abstract[197]|abstract[198]	new[197]|new[198]	_	_
27-49	4249-4252	the	abstract[197]|abstract[198]|substance[199]|abstract[200]	new[197]|new[198]|new[199]|new[200]	_	_
27-50	4253-4261	original	abstract[197]|abstract[198]|substance[199]|abstract[200]	new[197]|new[198]|new[199]|new[200]	_	_
27-51	4262-4270	medicine	abstract[197]|abstract[198]|substance[199]|abstract[200]	new[197]|new[198]|new[199]|new[200]	_	_
27-52	4271-4274	and	abstract[197]|abstract[198]|abstract[200]	new[197]|new[198]|new[200]	_	_
27-53	4275-4285	additional	abstract[197]|abstract[198]|abstract[200]|object[201]	new[197]|new[198]|new[200]|new[201]	coref	28-1[204_201]
27-54	4286-4296	excipients	abstract[197]|abstract[198]|abstract[200]|object[201]	new[197]|new[198]|new[200]|new[201]	_	_
27-55	4297-4299	or	abstract[197]|abstract[198]|abstract[200]	new[197]|new[198]|new[200]	_	_
27-56	4300-4305	their	abstract[197]|abstract[198]|abstract[200]|abstract[202]	new[197]|new[198]|new[200]|giv[202]	_	_
27-57	4306-4312	effect	abstract[197]|abstract[198]|abstract[200]|abstract[202]	new[197]|new[198]|new[200]|giv[202]	_	_
27-58	4313-4315	in	abstract[197]|abstract[198]|abstract[200]|abstract[202]	new[197]|new[198]|new[200]|giv[202]	_	_
27-59	4316-4324	children	abstract[197]|abstract[198]|abstract[200]|abstract[202]|person	new[197]|new[198]|new[200]|giv[202]|giv	coref	28-8
27-60	4325-4326	.	_	_	_	_

#Text=The excipients used in formulations designed for children should be appropriate for each age group because , as is known , these are not inert substances and cannot be supposed to have the same effects in pediatrics as in adults .
28-1	4327-4330	The	object[204]	giv[204]	coref	30-15[221_204]
28-2	4331-4341	excipients	object[204]	giv[204]	_	_
28-3	4342-4346	used	_	_	_	_
28-4	4347-4349	in	_	_	_	_
28-5	4350-4362	formulations	abstract	giv	coref	30-8[219_0]
28-6	4363-4371	designed	_	_	_	_
28-7	4372-4375	for	_	_	_	_
28-8	4376-4384	children	person	giv	ana	28-22
28-9	4385-4391	should	_	_	_	_
28-10	4392-4394	be	_	_	_	_
28-11	4395-4406	appropriate	_	_	_	_
28-12	4407-4410	for	_	_	_	_
28-13	4411-4415	each	abstract[208]	giv[208]	_	_
28-14	4416-4419	age	abstract|abstract[208]	giv|giv[208]	_	_
28-15	4420-4425	group	abstract[208]	giv[208]	_	_
28-16	4426-4433	because	_	_	_	_
28-17	4434-4435	,	_	_	_	_
28-18	4436-4438	as	_	_	_	_
28-19	4439-4441	is	_	_	_	_
28-20	4442-4447	known	_	_	_	_
28-21	4448-4449	,	_	_	_	_
28-22	4450-4455	these	person	giv	coref	29-6[215_0]
28-23	4456-4459	are	_	_	_	_
28-24	4460-4463	not	_	_	_	_
28-25	4464-4469	inert	substance[210]	giv[210]	_	_
28-26	4470-4480	substances	substance[210]	giv[210]	_	_
28-27	4481-4484	and	_	_	_	_
28-28	4485-4491	cannot	_	_	_	_
28-29	4492-4494	be	_	_	_	_
28-30	4495-4503	supposed	_	_	_	_
28-31	4504-4506	to	_	_	_	_
28-32	4507-4511	have	_	_	_	_
28-33	4512-4515	the	abstract[211]	new[211]	_	_
28-34	4516-4520	same	abstract[211]	new[211]	_	_
28-35	4521-4528	effects	abstract[211]	new[211]	_	_
28-36	4529-4531	in	abstract[211]	new[211]	_	_
28-37	4532-4542	pediatrics	abstract[211]|abstract	new[211]|giv	_	_
28-38	4543-4545	as	_	_	_	_
28-39	4546-4548	in	_	_	_	_
28-40	4549-4555	adults	_	_	_	_
28-41	4556-4557	.	_	_	_	_

#Text=The most common example is early stage children who are not able to metabolize or eliminate them as adults .
29-1	4558-4561	The	abstract[213]	new[213]	_	_
29-2	4562-4566	most	abstract[213]	new[213]	_	_
29-3	4567-4573	common	abstract[213]	new[213]	_	_
29-4	4574-4581	example	abstract[213]	new[213]	_	_
29-5	4582-4584	is	_	_	_	_
29-6	4585-4590	early	person[215]	giv[215]	ana	29-17[0_215]
29-7	4591-4596	stage	abstract|person[215]	new|giv[215]	_	_
29-8	4597-4605	children	person[215]	giv[215]	_	_
29-9	4606-4609	who	_	_	_	_
29-10	4610-4613	are	_	_	_	_
29-11	4614-4617	not	_	_	_	_
29-12	4618-4622	able	_	_	_	_
29-13	4623-4625	to	_	_	_	_
29-14	4626-4636	metabolize	_	_	_	_
29-15	4637-4639	or	_	_	_	_
29-16	4640-4649	eliminate	_	_	_	_
29-17	4650-4654	them	person	giv	_	_
29-18	4655-4657	as	_	_	_	_
29-19	4658-4664	adults	_	_	_	_
29-20	4665-4666	.	_	_	_	_

#Text=The ideal situation in the development of pediatric formulations is the minimal use of added excipients , both in number and quantity .
30-1	4667-4670	The	abstract[217]	new[217]	coref	30-11[220_217]
30-2	4671-4676	ideal	abstract[217]	new[217]	_	_
30-3	4677-4686	situation	abstract[217]	new[217]	_	_
30-4	4687-4689	in	abstract[217]	new[217]	_	_
30-5	4690-4693	the	abstract[217]|event[218]	new[217]|new[218]	_	_
30-6	4694-4705	development	abstract[217]|event[218]	new[217]|new[218]	_	_
30-7	4706-4708	of	abstract[217]|event[218]	new[217]|new[218]	_	_
30-8	4709-4718	pediatric	abstract[217]|event[218]|abstract[219]	new[217]|new[218]|giv[219]	_	_
30-9	4719-4731	formulations	abstract[217]|event[218]|abstract[219]	new[217]|new[218]|giv[219]	_	_
30-10	4732-4734	is	_	_	_	_
30-11	4735-4738	the	abstract[220]	giv[220]	_	_
30-12	4739-4746	minimal	abstract[220]	giv[220]	_	_
30-13	4747-4750	use	abstract[220]	giv[220]	_	_
30-14	4751-4753	of	abstract[220]	giv[220]	_	_
30-15	4754-4759	added	abstract[220]|object[221]	giv[220]|giv[221]	_	_
30-16	4760-4770	excipients	abstract[220]|object[221]	giv[220]|giv[221]	_	_
30-17	4771-4772	,	abstract[220]	giv[220]	_	_
30-18	4773-4777	both	abstract[220]	giv[220]	_	_
30-19	4778-4780	in	abstract[220]	giv[220]	_	_
30-20	4781-4787	number	abstract[220]|abstract	giv[220]|new	_	_
30-21	4788-4791	and	abstract[220]	giv[220]	_	_
30-22	4792-4800	quantity	abstract[220]|quantity	giv[220]|new	_	_
30-23	4801-4802	.	_	_	_	_
